DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway
文献类型：期刊论文
| 作者 | Chang, Shuaikang1; Li, Bo2; Xie, Yongsheng1; Wang, Yingcong1; Xu, Zhijian2 ; Jin, Shuhan1; Yu, Dandan1; Wang, Huaping1; Lu, Yumeng1; Zhang, Yong1
|
| 刊名 | NEOPLASIA
 |
| 出版日期 | 2022 |
| 卷号 | 24期号:1页码:50-61 |
| ISSN号 | 1476-5586 |
| 关键词 | Diffuse large B cell lymphoma DCZ0014 Apoptosis Lyn Syk |
| DOI | 10.1016/j.neo.2021.12.001 |
| 通讯作者 | Zhu, Weiliang(wlzhu@simm.ac.cn) ; Shi, Jumei(shijumei@tongji.edu.cn) |
| 英文摘要 | Diffuse large B cell lymphoma (DLBCL) is a clinical and genetically heterogeneous lymphoid malignancy. Although R-CHOP (rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment can improve the survival rate of patients with DLBCL, more than 30% of patients exhibit treatment failure, relapse, or refractory disease. Therefore, novel drugs or targeted therapies are needed to improve the survival of patients with DLBCL. The compound DCZ0014 is a novel chemical similar to berberine. In this study, we found that DCZ0014 significantly inhibited the proliferation and activity of DLBCL cells, and induced cell apoptosis. Following treatment with DCZ0014, DLBCL cells accumulated in G0/G1-phase of the cell cycle and showed decreased mitochondrial membrane potential. Additionally, DCZ0014 inhibited DNA synthesis, enhanced DNA damage in DLBCL cells, as well as inhibited Lyn/Syk in B cell receptor signaling pathway. Further experiments demonstrated that DCZ0014 did not significantly affect peripheral blood mononuclear cells. Tumor xenograft model showed that DCZ0014 not only inhibited tumor growth but also extended the survival time of mice. Thus, DCZ0014 showed potential for clinical application in the treatment of patients with DLBCL. |
| WOS关键词 | CHRONIC LYMPHOCYTIC-LEUKEMIA ; DNA-DAMAGE RESPONSE ; APOPTOSIS ; BERBERINE ; KINASE ; INHIBITOR ; ARREST ; GENE ; CARCINOGENESIS ; MECHANISMS |
| 资助项目 | National Natural Science Foundation of China[81670194] ; National Natural Science Foundation of China[81870158] ; National Natural Science Foundation of China[81900212] ; National Natural Science Foundation of China[81900211] ; National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China[:2018ZX09711002] ; Natural Science Foundation of Shanghai, China[19ZR1467800] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | ELSEVIER SCIENCE INC |
| WOS记录号 | WOS:000783312600004 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/299725]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhu, Weiliang; Shi, Jumei |
| 作者单位 | 1.Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Hematol, Shanghai 200072, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chang, Shuaikang,Li, Bo,Xie, Yongsheng,et al. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway[J]. NEOPLASIA,2022,24(1):50-61. |
| APA | Chang, Shuaikang.,Li, Bo.,Xie, Yongsheng.,Wang, Yingcong.,Xu, Zhijian.,...&Shi, Jumei.(2022).DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.NEOPLASIA,24(1),50-61. |
| MLA | Chang, Shuaikang,et al."DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway".NEOPLASIA 24.1(2022):50-61. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。